Acelyrin's CRO allegedly screwed up their clinical trial, resulting in a higher purported "response" from the placebo arm, and making their drug look ineffective. How many times have we seen clinical trials seemingly "fail" because of higher-than-expected placebo response rates? Several of us here can think of our small biotech investments that have been hammered this way. Funny how it doesn't seem to happen to BIG pharmas.

Quote:

---

ACELYRIN’s team recently identified clinical trial execution errors involving its CRO and one of the vendors engaged by the CRO. ACELYRIN has confirmed that the protocol, which outlined dosing sequence, was correct. However, ACELYRIN’s protocol was programmed incorrectly by the vendor, resulting in a sequencing error that went further unidentified through the providers’ testing processes. As a result, some patients in the 160mg Q2W and 80mg Q4W arms received placebo and active treatment in random order rather than in an alternating pattern as intended. https://finance.yahoo.com/news/acelyrin-inc-p...00979.html

---